Skip to content

Phone-Based Based Walk With Ease Program for Adults With Arthritis

Evaluating Alternative Delivery Models for Arthritis Self-management Interventions

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05289544
Enrollment
267
Registered
2022-03-21
Start date
2022-04-01
Completion date
2024-09-10
Last updated
2026-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Fibromyalgia, Gout, Lupus Erythematosus, Systemic, Osteoarthritis, Rheumatoid Arthritis

Keywords

Arthritis, Physical activity, Intervention

Brief summary

The objective of this study is to examine the short-term (6-weeks and 6 months) and long-term (1 year) effects of a phone-based version of Walk With Ease intervention.

Detailed description

Participants will be randomized to either start the 6-week program immediately or after one year. Our Walk with Ease by Telephone (WWE-T) program is adapted from the original 6-week community-based group walking program developed by the Arthritis Foundation for adults with arthritis. The phone-based program will include 2 phone calls each week with a trained Walk With Ease Leader for 6 weeks. Assessments will be completed before at the start of the study, 6 weeks, 6 months and at 12 months.

Interventions

BEHAVIORALPhone-Based Walk With Ease

6 week phone-delivered Walk With Ease Program

Sponsors

University of South Carolina
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* told by a doctor or other health professional that you have some form of arthritis, rheumatoid arthritis, gout, lupus, fibromyalgia * able to read and write in English * plan to live in the Columbia, SC region for next year * willing to be randomized to either group * complete all baseline measure

Exclusion criteria

* contraindications to exercise (besides arthritis) * are pregnant, breastfeeding, or planning to become pregnant in the next year * have a serious cognitive impairment

Design outcomes

Primary

MeasureTime frameDescription
Change in PainBaseline to 6 weeksVisual analog scale (0mm no/low pain to 100 mm high pain)
Change in Physical Function - Chair StandsBaseline to 6 weeksrepetitions completed during 30 second chair stand test
Change in Physical Function - 6 Minute WalkBaseline to 6 weeksDistance walked (ft) during 6 minute walk test

Secondary

MeasureTime frameDescription
Change in Physical LimitationsBaseline to 6 weeksHealth Assessment Questionnaire (HAQ) - Total score ranging from 0-3, with a higher score indicating more impairment or disability
Change in Physical ActivityBaseline to 6 weekstotal moderate and vigorous intensity physical activity (\>=2020 cpm) measured by Actigraph GT3x Link activity monitors
Change in Arthritis Management Self-efficacyBaseline to 6 weeksConfidence to manage symptoms of arthritis assessed by the Arthritis Self-Efficacy Scale. Total score 0-10 with higher scores indicating higher levels of self-efficacy for managing arthritis
Change in Blood PressureBaseline to 6 weeksDiastolic blood pressure measured in mmHg

Countries

United States

Baseline characteristics

Characteristic
Actigraph Measured moderate-vigorous intensity physical activity51.32 minutes/week
STANDARD_DEVIATION 10.36
Age, Continuous64.1 years
STANDARD_DEVIATION 9.4
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
Race (NIH/OMB)
Asian
3 Participants
Race (NIH/OMB)
Black or African American
160 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
5 Participants
Race (NIH/OMB)
White
98 Participants
Sex: Female, Male
Female
123 Participants
Sex: Female, Male
Male
12 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1320 / 135
other
Total, other adverse events
37 / 13228 / 135
serious
Total, serious adverse events
3 / 1320 / 135

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026